18 publications
Name | Date | Type | Actions |
---|---|---|---|
2024 half-year Results Sales: €264m (+3.2% as reported) |
Public releases | ||
2024 Half-Year Results slideshow Contents |
Half Year Report | ||
Rapport financier semestriel 2024 (French) Rapport financier semestriel 2024 (French) |
Half Year Report | ||
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases | ||
Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. |
Public releases | ||
Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates. |
Public releases | ||
Investor day 2017 Investor day 2017 |
Investor day |